The introduction of innovative weight-loss treatments has been a significant breakthrough in obesity management. The high prevalence of obesity, its strong association with deprivation, and its harmful impact on health, the NHS, and the economy are well recognised. But will the new treatments reduce these disparities or risk exacerbating existing inequalities in access and outcomes?
In this blog from nutritionist Issy McLaughlin and the Nutrition Intelligence Team at the British Nutrition Foundation, we look at why without increased accessibility and affordability, the rollout of weight loss medications may widen inequalities.
GLP-1 Weight Loss Drugs: A Breakthrough at Risk of Widening Health Inequalities?
Glucagon-like peptide-1 receptor agonists [1] (GLP-1s or GLP1-RAs), the weight management medications achieving up to 15%–25% weight loss in clinical trials, have reshaped the conversation about obesity since their approval for the weight loss in the UK in 2023. Given their effectiveness and scalability potential, drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) have been termed a “breakthrough” in tackling obesity in the government’s 10-Year Health Plan. But their rapid rise has also exposed something far less comfortable: GLP-1s, a breakthrough for whom?
Obesity is Not Equally Distributed, and Neither is Treatment
Disparities in healthy life expectancy are a critical public health challenge; people living in the most deprived areas experience almost 20 fewer years of good health than those in the least deprived areas. Obesity is a major contributor to health inequalities; obesity prevalence is nearly twice as high among people living in the most deprived compared with those in the least deprived areas (37.4% versus 19.8%). While the government has committed to halving the healthy life expectancy gap and launched a “moonshot to end the obesity epidemic”, there are questions about who is benefitting from GLP-1s. For example:
- approximately 4 million adults meet NICE criteria for tirzepatide yet NHS England’s phased rollout limits access to just 220,000 people in the first 3 years (~6%), prioritising people with a very high BMI and multiple health conditions.
- fewer than 200,000 people are currently estimated to be accessing GLP-1 medications through the NHS, but more than 1.4 million (>90% of users) may already be using them privately.
- recent survey analysis has found that people living in the most deprived areas were accessing 32% fewer private GLP-1 prescriptions than those living in the least deprived areas.
For households on the lowest incomes, the cost of medications (~£150 – £300 monthly) can represent a substantial proportion of disposable income.
| Quintile of disposable income
|
Median disposable income*
(£) |
Approx. GLP-1 medications cost
(% of annual disposable income) |
| Lowest | 16 800 | 25% |
| Highest | 71 100 | 5% |
The cost of private medication raises concerns that now access is increasingly determined by ability to pay rather than clinical need. It can also increase purchasing from cheaper unregulated sellers and consequent health risks from fake GLP1 medications.
As Health Secretary Wes Streeting has argued, a system reliant on private access risks becoming “a return to the days when health was determined by wealth“. Expanding access to all who would benefit is unaffordable, yet failing to do so is inequitable.
The Postcode Lottery
Access is shaped not only by income but also by geography. Funding allocated to Integrated Care Boards (ICBs) are currently sufficient to treat only a fraction of eligible patients. Combined with capacity constraints, availability varies considerably across the country. In December 2025, expenditure on Mounjaro was over £3 million in the Northeast and North Cumbria but only £1.7 million in nearby West Yorkshire despite having similar levels of obesity. Areas with the greatest obesity burden, which tend to be the most deprived, are often precisely the areas with the most stretched ICB budgets and the least specialist weight management infrastructure.
Behavioural Support
From a public health perspective, equity must extend beyond medication to include dietetic, behavioural, and lifestyle support. Wraparound care is associated with longer‑term success and prevention of weight regain following cessation of treatment, although the most effective and cost-effective support has not yet been elucidated. Evidence suggests around 50% of people choose to stop taking GLP-1s for reasons including side effects, cost for those self-funding or dissatisfaction with results. Average weight regain after discontinuation of treatment is often substantial, yet there is little support offered after cessation. While direct evidence on socioeconomic disparities in weight regain is scarce, there are plausible reasons to anticipate differential outcomes and vulnerability to weight regain. These include lower treatment adherence, early cessation/yo-yo medication, reduced access to comprehensive obesity care, and other adverse social determinants of health. We also know that disparities in diet and nutritional status already exist across levels of deprivation, alongside greater barriers to accessing and affording healthier food.
The Research Gaps
While weight loss medications have opened a new chapter in obesity treatment, there are significant gaps in what we know, many of which have equity implications.
More research is needed:
- Trial populations don’t reflect real-world need.
Landmark clinical trials enrolled predominantly white, higher-income participants. Black, South Asian, and lower-income populations carry the heaviest burden of metabolic disease yet are underrepresented in the evidence base.
- Nutritionally vulnerable groups.
Uncertainty remains on the long-term effects on growth, bone development, hormones, nutrition and energy balance in children and adolescents, as well as their impact on mental health and pregnancy outcomes.
- Wider impact on families:
How does GLP-1 use affect wider family wellbeing and mealtimes, and children’s dietary habits?
- Weight regain and GLP-1 “cycling”
How does repeatedly stopping and restarting GLP-1s impact weight loss, weight regain and health outcomes?
- Diet quality, food choice and food purchasing
Current evidence on how GLP-1s affect food intake and preferences is often self-reported, small-scale, and largely US-based. More representative UK data is needed. - Nutritional adequacy and body composition
There are concerns around reduced intakes of fibre, protein and micronutrients, as well as loss of muscle mass and bone density; fracture risks and longer-term implications are still unclear. - Effective adjunct behavioural therapy
More real-world evidence is needed to determine which approaches works best, which patients benefit most, and the optimal timing for when to start this support – whether at treatment initiation, when weight loss stalls or after medication is stopped
Prevention remains crucial
For many people, GLP-1s offer something that years of dieting, weight management programmes, and lifestyle advice have fallen short of achieving: meaningful and sustained weight loss. Without increased accessibility and lower costs, the rollout of GLP1s may widen inequalities. To maximise the benefits, we need to deploy these medications in ways that are cost effective, sustainable for healthcare systems, and equitable for societies.
However, they are not a silver bullet and address the symptom, not the cause. With 66% UK adults living with overweight or obesity, a focus on prevention is critical in tackling the underlying factors contributing to obesity. Comprehensive policies and systematic approaches aimed at improving the food environment, the affordability and accessibility of healthier foods, and mitigating food insecurity are urgently needed.
[1] For ease we will refer to these medications as GLP-1s in the text
References
NICE (2025) Tirzepatide for managing overweight and obesity. Available at: https://www.nice.org.uk/guidance/ta1026/informationforpublic
MHRA (2023) MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss. Available at: https://www.gov.uk/government/news/mhra-authorises-diabetes-drug-mounjaro-tirzepatide-for-weight-management-and-weight-loss
DHSC (2025) 10 Year Health Plan for England: fit for the future. Available at: https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future
ONS (2026) Healthy life expectancy by national area deprivation, England and Wales: between 2013 to 2015 and 2022 to 2024. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthinequalities/bulletins/healthylifeexpectancybynationalareadeprivationenglandandwales/between2013to2015and2022to2024
OHID (2025) Obesity profile: short statistical commentary, May 2025. Available at: https://www.gov.uk/government/statistics/obesity-profile-may-2025-update/obesity-profile-short-statistical-commentary-may-2025
The Health Foundation (2026) New data reveal inequalities in access to private GLP-1 weight loss drugs as demand surges. Available at: https://www.health.org.uk/media-office/press-releases/new-data-reveal-inequalities-in-access-to-private-glp-1-weight-loss-drugs-as-demand-surges
NHS England (2026) Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity. Available at: https://www.england.nhs.uk/publication/interim-commissioning-guidance-implementation-of-the-nice-technology-appraisal-ta1026-and-the-nice-funding-variation-for-tirzepatide-mounjaro-for-the-management-of-obesity/
The King’s Fund (2025) GLP-1 drugs on the NHS: Can, and should, we roll them out at scale? Available at: https://www.kingsfund.org.uk/insight-and-analysis/blogs/glp-1-drugs-nhs-should-roll-them-out-at-scale
UK Parliament (2026) Health and Social Care Committee: Food and Weight Management Inquiry. Written Evidence Submitted by Manesha Banwait at IQVIA (FWM0029). Available at: https://committees.parliament.uk/writtenevidence/146947/pdf
The Health Foundation (2026) GLP‑1 drug prescriptions for obesity. Who is turning to private weight‑loss treatment? Available at: https://www.health.org.uk/reports-and-analysis/analysis/glp-1-drug-prescriptions-for-obesity
The Care Pharmacy (2026) Mounjaro Price Comparison UK (2026): The Complete Guide. Available at: https://thecarepharmacy.com/mounjaro-price-comparison-uk/
The Health Foundation (2025) GLP-1 receptor agonists: a wake-up call for the food system, not a silver bullet for obesity. Available at: https://www.health.org.uk/features-and-opinion/blogs/glp-1-receptor-agonists-a-wake-up-call-for-the-food-system-not-a-silver
Open Prescribing (2026) Search GP Prescribing Data. Available at: https://openprescribing.net/analyse/#org=stp&numIds=0601023AZBB&denom=nothing&selectedTab=map
OHID (2026) Public Health Profiles. Available at: https://fingertips.phe.org.uk/profile/obesity-physical-activity-nutrition/data#page/3/gid/1938133368/pat/15/par/E92000001/ati/6/are/E12000004/iid/93088/age/168/sex/4/cat/-1/ctp/-1/yrr/1/cid/4/tbm/1/page-options/tre-do-1
Mozaffarian D, Agarwal M, Aggarwal M, Alexander L, Apovian CM, Bindlish S et al. (2025) Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine 15598276251344827. doi: 10.1177/15598276251344827. Epub ahead of print. PMID: 40452753; PMCID: PMC12125019.
Weight regain after cessation of medication for weight management: systematic review and meta-analysis doi:10.1136/bmj-2025-085304
Jeyakumar Y, Richardson L, Sarma S, Retnakaran R, Kramer CK (2024) Representation of racialised and ethnically diverse populations in multicentre randomised controlled trials of GLP-1 medicines for obesity: a systematic review and meta-analysis of gaps. BMJ Glob Health 9(11):e017177. doi: 10.1136/bmjgh-2024-017177. PMID: 39608857; PMCID: PMC11603712.
HCP Live (2025) Demographic Disparities in GLP-1 RA Trial Enrollment Raise Inclusivity, Validity Concerns. Available at: https://www.hcplive.com/view/demographic-disparities-in-glp-1-ra-trial-enrollment-raise-inclusivity-validity-concerns
OHID (2025) Obesity profile: short statistical commentary, May 2025. Available at: https://www.gov.uk/government/statistics/obesity-profile-may-2025-update/obesity-profile-short-statistical-commentary-may-2025
ONS (2025) Average household income, UK: Financial Year Ending 2024. Available at: https://backup.ons.gov.uk/wp-content/uploads/sites/3/2025/05/Average-household-income-UK-Financial-Year-Ending-2024.pdf
